[{"data":1,"prerenderedAt":124},["Reactive",2],{"site-settings-en":3,"7bhrETXDtE":40,"1hFe7Vy99q":57},{"errors":4,"messages":5,"details":6},[],[],{"topics_id":7,"ymd":8,"contents_type":9,"subject":10,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":13,"update_ymdhi":14,"topics_group_id":15,"slug":16,"lang_open_flg":11,"group_nm":10,"group_description":17,"contents_type_cnt":11,"contents_type_nm":10,"contents_type_slug":18,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":18,"contents_type_ext_col_02":18,"contents_type_ext_col_03":18,"contents_type_ext_col_04":18,"contents_type_ext_col_05":18,"contents_type_list":19,"navigation_link_color":20,"navigation_link_hover_color":21,"navigation_links":22,"show_archives":35,"archive_title_border_color":21,"archive_title_background_color":38,"category_label_color":38,"company_label_color":39},25,"1970-01-01",21,"サイト全体設定",1,0,"2025-09-24T10:49:31+09:00","2025-11-10T11:29:04+09:00",10,"site_setting","全ページに使われている共通パーツの設定",null,[9],"#2e3538","#a88dfc",[23,26,29,32],{"url":24,"title":25},"/en/company/","Company Information",{"url":27,"title":28},"/en/esg/","ESG / Sustainability",{"url":30,"title":31},"/en/news","News",{"url":33,"title":34},"/en/contact","Contact",{"key":36,"label":37},"1","表示","#dcd2fc","#ece8fa",{"errors":41,"messages":42,"details":43},[],[],{"topics_id":44,"ymd":45,"contents_type":46,"contents":47,"subject":48,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":49,"update_ymdhi":50,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":52,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":51,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":53,"company":54,"link":51},32,"2026-08-13",23,"\u003Cp>On June 25, 2026, OSferionBiomaterials Corp. (OSB), a member of OrthoActiVolution Holdings Inc. (OAV), was selected for the FY2027 Medical Device Industry Infrastructure Enhancement Grant (R&D and Commercialization Program), administered by the Shizuoka Industrial Foundation.\u003C/p>\u003Cp>\u003Cbr>This grant supports initiatives aimed at strengthening the foundation of the vital healthcare industry through the promotion of domestic pharmaceutical and medical device manufacturing, digital transformation, and the development of remote and contactless healthcare solutions.\u003C/p>\u003Cp>\u003Cbr>Through this grant, OSferionBiomaterials (OSB) will continue to advance the research, development, and commercialization of innovative technologies and products in the medical device field.\u003C/p>\u003Cp> \u003C/p>\u003Cp>For more information (Japanese) (External Link): \u003Ca href=\"https://www.biomaterial.co.jp/news/201/\" target=\"_blank\" rel=\"noopener noreferrer\">https://www.biomaterial.co.jp/news/201/\u003C/a>\u003C/p>","OSferionBiomaterials Selected for FY2027 Medical Device Industry Enhancement Grant (R&D and Commercialization Program)","2026-09-16T10:33:46+09:00","2026-09-30T17:42:24+09:00","","News Release",[46],{"key":55,"label":56},"2","OSferionBiomaterials Corp.",{"errors":58,"messages":59,"list":60,"pageInfo":122},[],[],[61,64,72,83,92,100,112],{"topics_id":44,"ymd":45,"contents_type":46,"contents":47,"subject":48,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":49,"update_ymdhi":50,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":52,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":51,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":62,"company":63,"link":51},[46],{"key":55,"label":56},{"topics_id":65,"ymd":45,"contents_type":46,"contents":66,"subject":67,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":68,"update_ymdhi":69,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":52,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":51,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":70,"company":71,"link":51},31,"\u003Cp>OSferionBiomaterials Corp. (OSB), a member of OrthoActiVolution Holdings Inc. (OAV), was selected on July 21, 2026, as a recipient of the FY2027 Intensive Support Program for Next-Generation Medical Device Development and Commercialization, administered by the Fujinokuni Medical Town Promotion Organization.\u003C/p>\u003Cp>\u003Cbr>The program is designed to revitalize Shizuoka Prefecture’s medical and healthcare industry by creating model cases of advanced medical device development led by highly capable local companies and encouraging broader participation by other innovative businesses.\u003C/p>\u003Cp>\u003Cbr>Through this support, OAV and OSferionBiomaterials (OSB) will continue itheir efforts to develop high-performance medical devices and contribute to the growth of the medical and healthcare industry.\u003Cbr> \u003C/p>\u003Cp>For more information (Japanese) (External Link): \u003Ca href=\"https://www.biomaterial.co.jp/news/199/\" target=\"_blank\" rel=\"noopener noreferrer\">https://www.biomaterial.co.jp/news/199/\u003C/a>\u003C/p>","OSferionBiomaterials Selected as a Recipient of the FY2027 Intensive Support Program for Next-Generation Medical Device Development and Commercialization","2026-09-16T09:52:03+09:00","2026-09-30T17:17:47+09:00",[46],{"key":55,"label":56},{"topics_id":73,"ymd":74,"contents_type":75,"contents":76,"subject":77,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":78,"update_ymdhi":79,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":80,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":80,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":81,"company":82,"link":51},30,"2026-07-27",17,"\u003Cp>OSferionBiomaterials Corp. (Headquarters: Shibuya Ward, Tokyo, President: Manabu Ishikawa, hereinafter referred to as OSB) and Japan Tissue Engineering Co., Ltd. (Headquarters: Gamagori City, Aichi Prefecture, President: Kazuto Yamada, hereinafter referred to as J-TEC) have entered into a business alliance agreement to promote a treatment option for osteoarthritis of the knee that combines regenerative medicine and osteotomy. The two companies will begin mutual product development and joint promotions from August 2026.\u003Cbr> \u003C/p>\u003Cp>*For more detail information (External Link) (in Japanese) : \u003Ca href=\"https://www.biomaterial.co.jp/news/192/\">オスフェリオンバイオマテリアルとジャパン・ティッシュエンジニアリング再生医療と骨切り術を組み合わせた膝関節温存治療に向け業務提携 | お知らせ | オスフェリオンバイオマテリアル株式会社\u003C/a>\u003C/p>","OSferionBiomaterials Corp. and Japan Tissue Engineering Co., Ltd. form business alliance to develop knee joint preservation treatment combining regenerative medicine and osteotomy.","2026-07-27T13:05:30+09:00","2026-09-30T17:29:30+09:00","Press Release",[75],{"key":55,"label":56},{"topics_id":84,"ymd":85,"contents_type":46,"contents":86,"subject":87,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":88,"update_ymdhi":89,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":52,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":51,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":90,"company":91,"link":51},29,"2025-12-17","\u003Cp>On October 27, 2025, OSferionBiomaterials Corp., a member of our group, was selected as a supported company under the “FY2026 Intensive Support Program for Next-Generation Medical Device Development and Commercialization,” administered by the Fujinokuni Medical Town Promotion Organization.\u003Cbr>This program aims to revitalize Shizuoka Prefecture’s medical and healthcare industry by creating model cases of advanced medical device development by highly skilled local companies and fostering a positive cycle that encourages the entry of other outstanding businesses.\u003Cbr>Leveraging this support, our company will continue to contribute to the development of high-performance medical devices and the growth of the medical and healthcare industry.\u003C/p>","Selected as a Supported Company under the FY2026 Intensive Support Program for Next-Generation Medical Device Development and Commercialization","2025-12-17T17:05:16+09:00","2025-12-24T13:41:57+09:00",[46],{"key":55,"label":56},{"topics_id":93,"ymd":85,"contents_type":46,"contents":94,"subject":95,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":96,"update_ymdhi":97,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":52,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":51,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":98,"company":99,"link":51},28,"\u003Cp>On June 26, 2025, OSferionBiomaterials Corp., a member of our group, was selected for the “FY2026 Medical Device Industry Infrastructure Enhancement Grant (Initial Investment Support Program)” administered by the Shizuoka Industrial Foundation.\u003Cbr>This grant supports initiatives aimed at strengthening the foundation of the medical device industry - an industry that safeguards lives - by promoting domestic industrialization of pharmaceuticals and medical devices, advancing digitalization, and enabling remote and contactless solutions.\u003Cbr>Leveraging this grant, our company will continue to pursue research and development of new technologies and products in the medical device field, as well as their commercialization.\u003C/p>","Selected for the FY2026 Medical Device Industry Infrastructure Enhancement Grant (Initial Investment Support Program)","2025-12-17T16:53:03+09:00","2025-12-24T13:40:47+09:00",[46],{"key":55,"label":56},{"topics_id":101,"ymd":102,"contents_type":46,"contents":103,"subject":104,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":105,"update_ymdhi":106,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":52,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":51,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":107,"company":108,"link":111},27,"2025-11-10","\u003Cp>External Link:：\u003Ca href=\"https://www.fhortho.com/en/news/visit-of-japanese-consul-yusuke-uchikawa/\" target=\"_blank\" rel=\"noopener noreferrer\">hhttps://www.fhortho.com/en/news/visit-of-japanese-consul-yusuke-uchikawa/\u003C/a>\u003C/p>","Visit of Japanese Consul","2025-11-10T11:12:03+09:00","2025-11-26T16:23:58+09:00",[46],{"key":109,"label":110},"3","FH ORTHO SAS","https://www.fhortho.com/en/news/visit-of-japanese-consul-yusuke-uchikawa/",{"topics_id":113,"ymd":114,"contents_type":75,"contents":115,"subject":116,"topics_flg":11,"open_flg":11,"regular_flg":12,"inst_ymdhi":117,"update_ymdhi":118,"topics_group_id":11,"slug":51,"lang_open_flg":11,"group_nm":31,"group_description":51,"contents_type_cnt":11,"contents_type_nm":80,"contents_type_slug":51,"contents_type_parent_nm":18,"category_parent_id":18,"contents_type_ext_col_01":80,"contents_type_ext_col_02":51,"contents_type_ext_col_03":51,"contents_type_ext_col_04":51,"contents_type_ext_col_05":51,"contents_type_list":119,"company":120,"link":121},26,"2025-04-01","\u003Cp>External Link:：\u003Ca href=\"https://www.biomaterial.co.jp/en/news/139/\" target=\"_blank\" rel=\"noopener noreferrer\">https://www.biomaterial.co.jp/en/news/139/\u003C/a>\u003C/p>","Notice regarding change of company name (trade name) of group company","2025-11-10T11:10:40+09:00","2025-11-10T11:34:50+09:00",[75],{"key":55,"label":56},"https://www.biomaterial.co.jp/en/news/139/",{"totalCnt":123},7,1791514295538]